New FDA guidance on addressing misinformation under White House review
Agency IQ
MAY 28, 2024
BY LAURA DIANGELO, MPH A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA).
Let's personalize your content